MedTrace Logo

Gastrointestinal Endoscopy Artificial Intelligence Cloud Platform in Gastrointestinal Endoscopy Screening

NCT05435872 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2022-07-12

No results posted yet for this study

Summary

Study objective: To establish a quality control system for gastrointestinal endoscopy based on artificial intelligence technology and an auxiliary diagnosis system that can perform lesion identification, improving the detection rate of early gastrointestinal cancer while standardizing, normalizing, and homogenizing the endoscopic treatment in primary hospitals (including some of the primary hospitals, which are participating in Beijing-Tianjin-Hebei Gastrointestinal Endoscopy Medical Consortium) under Gastrointestinal Endoscopy Artificial Intelligence Cloud Platform as the hardware base.

Study design: This study is a prospective, multi-center, real-world study.

Conditions

  • Diagnoses Disease
  • Quality Control
  • Endoscopy
  • Artificial Intelligence

Interventions

DEVICE

The Artificial intelligence Cloud Platform

The Artificial intelligence Cloud Platform would be used as the auxiliary device for endoscopists during the whole endoscopic examination to help endoscopists complete the quality control, indicate potential lesions, and aid in diagnosis.

Sponsors & Collaborators

  • Beijing Aerospace General Hospital

    collaborator OTHER

  • Beijing Fangshan District Liangxiang Hospital

    collaborator OTHER

  • People's Hospital of Beijing Daxing District

    collaborator OTHER

  • Gucheng County Hospital of Hebei Province

    collaborator UNKNOWN

  • Nanhe County Hospital of Hebei Province

    collaborator UNKNOWN

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Aiming Yang, M.D. · Peking Union Medical College Hospital

  • Shengyu Zhang · Peking Union Medical College Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-09
Primary Completion
2024-02-01
Completion
2024-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05435872 on ClinicalTrials.gov